Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,769
archived clinical trials in
Migraine Headaches

To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Regional Clinical Research, Inc.
mi
from
Endwell, NY
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Regional Clinical Research, Inc.
mi
from
Endwell, NY
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Central New York Clinical Research
mi
from
Manlius, NY
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Central New York Clinical Research
mi
from
Manlius, NY
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Clinilabs Inc.
mi
from
New York, NY
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Clinilabs Inc.
mi
from
New York, NY
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Rochester Clinical Research Inc.
mi
from
Rochester, NY
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Rochester Clinical Research Inc.
mi
from
Rochester, NY
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Upstate Clinical Research Associates
mi
from
Williamsville, NY
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Upstate Clinical Research Associates
mi
from
Williamsville, NY
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Plains Medical Clinic
mi
from
Fargo, ND
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Plains Medical Clinic
mi
from
Fargo, ND
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Radiant Akron
mi
from
Akron, OH
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Radiant Akron
mi
from
Akron, OH
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Radiant Research - Cincinnati
mi
from
Cincinnati, OH
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Radiant Research - Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Rapid Medical Research, Inc.
mi
from
Cleveland, OH
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Rapid Medical Research, Inc.
mi
from
Cleveland, OH
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Ohio Clinical Research
mi
from
Lyndhurst, OH
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Ohio Clinical Research
mi
from
Lyndhurst, OH
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
IPS Research Company
mi
from
Oklahoma City, OK
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
IPS Research Company
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Lynn Health Science Institute
mi
from
Oklahoma City, OK
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Lynn Health Science Institute
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Summit Research Network
mi
from
Portland, OR
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Summit Research Network
mi
from
Portland, OR
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Oregon Center for Clinical Investigations, Inc
mi
from
Salem, OR
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Oregon Center for Clinical Investigations, Inc
mi
from
Salem, OR
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Lehigh Center for Clinical Research
mi
from
Allentown, PA
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Lehigh Center for Clinical Research
mi
from
Allentown, PA
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Suburban Research Associates
mi
from
Media, PA
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Suburban Research Associates
mi
from
Media, PA
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Clinical Research of Philadelphia LLC
mi
from
Philadelphia, PA
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Clinical Research of Philadelphia LLC
mi
from
Philadelphia, PA
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Frontier Clinical Research, LLC
mi
from
Scottdale, PA
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Frontier Clinical Research, LLC
mi
from
Scottdale, PA
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Frontier Clinical Research, LLC
mi
from
Smithfield, PA
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Frontier Clinical Research, LLC
mi
from
Smithfield, PA
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Radiant Research, Inc.
mi
from
Anderson, SC
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Radiant Research, Inc.
mi
from
Anderson, SC
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Coastal Carolina Research Center
mi
from
Mount Pleasant, SC
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Coastal Carolina Research Center
mi
from
Mount Pleasant, SC
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Meridian Clinical Research
mi
from
Dakota Dunes, SD
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Meridian Clinical Research
mi
from
Dakota Dunes, SD
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Volunteer Research Group
mi
from
Knoxville, TN
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Volunteer Research Group
mi
from
Knoxville, TN
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
CNS Healthcare of Memphis
mi
from
Memphis, TN
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
CNS Healthcare of Memphis
mi
from
Memphis, TN
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Trinity Clinical Research
mi
from
Tullahoma, TN
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Trinity Clinical Research
mi
from
Tullahoma, TN
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Tekton Research
mi
from
Austin, TX
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Tekton Research
mi
from
Austin, TX
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
DiscoveResearch, Inc.
mi
from
Bryan, TX
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
DiscoveResearch, Inc.
mi
from
Bryan, TX
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
FutureSearch Trials
mi
from
Dallas, TX
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
FutureSearch Trials
mi
from
Dallas, TX
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Earle Research
mi
from
Houston, TX
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Earle Research
mi
from
Houston, TX
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Research Trials Worldwide LLC
mi
from
Humble, TX
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Research Trials Worldwide LLC
mi
from
Humble, TX
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Radiant Research - San Antonio
mi
from
San Antonio, TX
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Radiant Research - San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
ClinPoint Trials, LLC
mi
from
Waxahachie, TX
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
ClinPoint Trials, LLC
mi
from
Waxahachie, TX
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Foothill Family Draper Clinic
mi
from
Draper, UT
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Foothill Family Draper Clinic
mi
from
Draper, UT
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Advanced Research Institute
mi
from
Ogden, UT
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Advanced Research Institute
mi
from
Ogden, UT
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Advanced Clinical Research, Inc.
mi
from
West Jordan, UT
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Advanced Clinical Research, Inc.
mi
from
West Jordan, UT
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Charlottesville Medical Research Inc.
mi
from
Charlottesville, VA
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Charlottesville Medical Research Inc.
mi
from
Charlottesville, VA
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Associates of Tidewater
mi
from
Norfolk, VA
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Associates of Tidewater
mi
from
Norfolk, VA
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Tidewater Integrated Medical Research
mi
from
Virginia Beach, VA
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Tidewater Integrated Medical Research
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Northwest Clinical Research Center
mi
from
Bellevue, WA
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Northwest Clinical Research Center
mi
from
Bellevue, WA
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
North Seattle Womens Group
mi
from
Seattle, WA
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
North Seattle Womens Group
mi
from
Seattle, WA
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
SSM Dean Health Research
mi
from
Madison, WI
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
SSM Dean Health Research
mi
from
Madison, WI
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
FutureSearch Trials of Neurology
mi
from
Austin, TX
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
FutureSearch Trials of Neurology
mi
from
Austin, TX
Click here to add this to my saved trials
Pharmacokinetics (PK), Safety, and Tolerability of M207 at Two App Sites With Intranasal Zolmitriptan 2.5 mg in Healthy Volunteers
A Randomized Open-label Four-way Crossover Study to Compare the PK, Safety, and Tolerability of M207 3.8 mg (Administered as Two 1.9 mg Patches) at Two Different Application Locations (Upper Arm and Thigh) for 30 Minutes With Intranasal Zolmitriptan 2.5 mg and 1 Hour Wear Time (Upper Arm) in Healthy Volunteers
Status: Enrolling
Updated:  12/31/1969
Hill Top Research, Inc.
mi
from
Neptune, NJ
Pharmacokinetics (PK), Safety, and Tolerability of M207 at Two App Sites With Intranasal Zolmitriptan 2.5 mg in Healthy Volunteers
A Randomized Open-label Four-way Crossover Study to Compare the PK, Safety, and Tolerability of M207 3.8 mg (Administered as Two 1.9 mg Patches) at Two Different Application Locations (Upper Arm and Thigh) for 30 Minutes With Intranasal Zolmitriptan 2.5 mg and 1 Hour Wear Time (Upper Arm) in Healthy Volunteers
Status: Enrolling
Updated: 12/31/1969
Hill Top Research, Inc.
mi
from
Neptune, NJ
Click here to add this to my saved trials
Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines
Parenteral Corticosteroids as Adjuvant Therapy for Migraine Headaches
Status: Enrolling
Updated:  12/31/1969
Jacobi Medical Center
mi
from
Bronx, NY
Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines
Parenteral Corticosteroids as Adjuvant Therapy for Migraine Headaches
Status: Enrolling
Updated: 12/31/1969
Jacobi Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines
Parenteral Corticosteroids as Adjuvant Therapy for Migraine Headaches
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center
mi
from
Manhattan, NY
Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines
Parenteral Corticosteroids as Adjuvant Therapy for Migraine Headaches
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center
mi
from
Manhattan, NY
Click here to add this to my saved trials
Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines
Parenteral Corticosteroids as Adjuvant Therapy for Migraine Headaches
Status: Enrolling
Updated:  12/31/1969
St. Luke's Hospital
mi
from
New York, NY
Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines
Parenteral Corticosteroids as Adjuvant Therapy for Migraine Headaches
Status: Enrolling
Updated: 12/31/1969
St. Luke's Hospital
mi
from
New York, NY
Click here to add this to my saved trials
High School Start Time and Teen Migraine Frequency
High School Start Time and Adolescent Migraine Frequency
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
High School Start Time and Teen Migraine Frequency
High School Start Time and Adolescent Migraine Frequency
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
Click here to add this to my saved trials
Adherence to and Beliefs on Recommendations for Behavioral Treatment for Migraine
Adherence to and Beliefs on Recommendations for Behavioral Treatment for Migraine
Status: Enrolling
Updated:  12/31/1969
NYU Langone
mi
from
New York, NY
Adherence to and Beliefs on Recommendations for Behavioral Treatment for Migraine
Adherence to and Beliefs on Recommendations for Behavioral Treatment for Migraine
Status: Enrolling
Updated: 12/31/1969
NYU Langone
mi
from
New York, NY
Click here to add this to my saved trials
ESCAPE Migraine Trial
Effect of Septal Closure of Atrial PFO on Events of Migraine With Premere: ESCAPE Migraine Trial
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Hospital
mi
from
Scottsdale, AZ
ESCAPE Migraine Trial
Effect of Septal Closure of Atrial PFO on Events of Migraine With Premere: ESCAPE Migraine Trial
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Hospital
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
ESCAPE Migraine Trial
Effect of Septal Closure of Atrial PFO on Events of Migraine With Premere: ESCAPE Migraine Trial
Status: Enrolling
Updated:  12/31/1969
Newport Beach Clinical Research Associates, Inc.
mi
from
Newport Beach, CA
ESCAPE Migraine Trial
Effect of Septal Closure of Atrial PFO on Events of Migraine With Premere: ESCAPE Migraine Trial
Status: Enrolling
Updated: 12/31/1969
Newport Beach Clinical Research Associates, Inc.
mi
from
Newport Beach, CA
Click here to add this to my saved trials